Biogen discontinues Apellis programs post $5.6B acquisition, reallocating resources to Empaveli and Syfovre. U.S. begins ...

Biogen Canada Inc. is disappointed that negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for SKYCLARYS™ ...

From persevering with a tricky Alzheimer’s program to securing a late-stage CD38-directed antibody and posting encouraging lupus data, Biogen has remained in the news recently—and that’s no accident.

Quince Therapeutics Inc. stock grades by Barron's. View QNCX fundamental and sentiment analysis powered by MarketGrader.

Biogen shares dropped 6.4% after Phase 2 CELIA trial data revealed information absent from the Company's filings. Biogen published a press release on May 14, 2026, announcing that CELIA did not meet ...

Biogen plans to advance an experimental drug for Alzheimer's disease to late-stage testing despite disappointing mid-stage trial data, the company said Thursday. Biogen plans to move the drug into ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Biogen is acquiring Apellis Pharmaceuticals in a $5.6 billion deal that brings two FDA-approved products commercialized in four indications, all of which are expected to contribute to the revenue ...

Biogen BIIB0.05%increase; up pointing triangle agreed to acquire Apellis Pharmaceuticals for approximately $5.6 billion, expanding its portfolio in immunology and rare-disease medicines. Under the ...

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

Please provide your email address to receive an email when new articles are posted on . The acquisition includes Syfovre for geographic atrophy and Empaveli for two rare kidney diseases and paroxysmal ...

Biogen Balances Solid 2025 Performance With Cautious 2026 Outlook Biogen’s latest earnings call struck a tone of guarded optimism. Management highlighted better‑than‑expected earnings, strong cash ...